GLP-1 receptor agonists do not appear to suppress male reproductive hormones in healthy men, and may improve testosterone and semen parameters in obese men with hypogonadism — here is what the ENDO 2026 research shows. ...
Dr. Norena Velasquez[/caption]
MedicalResearch.com Interview with:
Jairo Norena Velasquez, MD
Associate Division Chief, Endocrinology Division
Alameda Health System
Oakland, California
Response: Type 2 diabetes is associated with a paradoxically elevated fracture risk — up to three times higher than the general population — despite normal or even elevated bone mineral density. The underlying problem is poor bone quality driven by chronic hyperglycemia, advanced glycation end-product accumulation, and increased cortical porosity. Compounding this, intentional weight loss — a cornerstone of diabetes treatment — can accelerate bone loss by reducing mechanical loading on the skeleton.
Semaglutide is one of the most effective weight-loss agents available, yet direct real-world comparisons of its skeletal effects against other active weight-loss therapies were lacking.
Using the Atropos Health Eos EHR database — 161 million US patients from 2016 to 2023 — we compared fracture incidence and BMI change in adults with type 2 diabetes initiating semaglutide versus dulaglutide, phentermine/topiramate, or bupropion/naltrexone, using high-dimensional propensity score matching (17,506 pairs per group).
Semaglutide was associated with greater weight loss (mean delta BMI −1.9 vs. −1.2 kg/m²; difference −0.72 kg/m², p < 0.001) and a 15% reduction in fracture incidence (HR 0.85, 95% CI 0.77–0.93; p < 0.001) over a mean follow-up of 3.6 years.
Important Notice: Importing medications from Canada is not legal in all U.S. states. Most weight loss medications require a valid prescription and should be monitored by a qualified healthcare provider. Medications imported from Canada may not be FDA-tested or FDA-approved for use in the United States. MedicalResearch.com and Eminent Domains Inc. does not warrant, endorse, or recommend any imported medication, supplier, or product referenced in this post. This content is provided for educational purposes only. Always consult a licensed healthcare provider before starting, changing, or stopping any medication.
Weight loss is often discussed in terms of appearance, fitness, or medical outcomes, but its connection to mental well-being deserves equal attention. The process of changing lifestyle habits can influence mood, confidence, daily energy levels, and overall quality of life. At the same time, emotional challenges can affect eating patterns, activity levels, and long-term success. Understanding the connection between weight and the mind helps people approach change in a more balanced and sustainable way.
Supplement Notice: Berberine is a dietary supplement and is not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, or prevent any disease. It is not a substitute for prescription medications including metformin, semaglutide (Ozempic/Wegovy), or any other FDA-approved therapy. Berberine can interact with prescription medications including warfarin, cyclosporine, and metformin. Do not use berberine as a replacement for prescribed treatment without consulting your physician. Always seek the advice of a qualified healthcare provider before starting any supplement regimen.
Few supplements have had a more dramatic cultural moment than berberine. Once confined to the shelves of specialty health stores and the protocols of integrative medicine practitioners, berberine has become something of a phenomenon — propelled partly by social media comparisons to semaglutide (sold as Ozempic and Wegovy), a prescription GLP-1 receptor agonist that has transformed the treatment of type 2 diabetes and obesity. The comparison has a surface-level appeal. Both compounds influence metabolic pathways involved in blood sugar regulation. Both are discussed in the context of weight management. Berberine is a fraction of the cost, available without a prescription, and marketed across wellness channels as a "natural" alternative. The shorthand — "nature's Ozempic" — spread quickly and widely. The problem is that shorthand compresses a complicated evidence picture into a slogan. What the randomized controlled trial (RCT) evidence on berberine actually shows is more interesting — and more nuanced — than either its most enthusiastic proponents or its dismissers tend to acknowledge.
Phase 3 SYNCHRONIZE-1 trial data shows survodutide achieves up to 16.6% average weight loss with targeted visceral fat reduction and significant liver fat improvements — presented at ADA 2026....
Dr. Fuemmeler[/caption]
Bernard F. Fuemmeler, PhD, MPH
Professor and Gordon D. Ginder, MD Chair in Cancer Research
Associate Director of Population Science, Massey Comprehensive Cancer Center
Director of Research, Family Medicine and Population Health
[caption id="attachment_73640" align="alignleft" width="125"]
Dr. Tatum[/caption]
Kristina L. Tatum, PsyD, MS
Instructor
Department of Social and Behavioral Sciences
School of Public Health
A large population-based analysis of more than 841,000 breast cancer patients across the United States examines whether GLP-1 receptor agonist use is associated with improved survival and lower recurrence risk — with findings that researchers describe as very promising.
